ClinicalTrials.gg
CompletedNCT03251248Updated Jul 2, 2019

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

A Phase 1 interventional study of MSB11455 and Neulasta in Healthy, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2018, 8 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of MSB11455 and Neulasta in healthy adult subjects.

02

Conditions studied

  • Healthy

Keywords

  • MSB11455
  • Healthy subjects
03

In context

Lead sponsor

Fresenius Kabi SwissBioSim GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who provide signed and dated written
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Subjects who have no known to any component of Neulasta or MSB11455, and laboratory test results within predefined ranges
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    First MSB11455 Then Neulasta

    Drug: MSB11455 · Drug: Neulasta

  • Experimental
    First Neulasta Then MSB11455

    Drug: MSB11455 · Drug: Neulasta

Interventions

  • Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.

  • Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.

    Also known as: pegfilgrastim

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero (Pre-dose) to Time of Last Quantifiable Concentration AUC(0-last) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  2. Area Under the Concentration-Time Curve From Time Zero (Pre-dose) Extrapolated to Infinity AUC(0-inf) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  4. Maximum Observed Effect (Emax) for Absolute Neutrophil Count (ANC) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  5. Area Under the Effect-Time Curve From Time Zero (Pre-dose) to Last Measured Time (AUE0-t) for (ANC) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

Secondary outcomes

  1. Time to Maximum Observed Plasma Concentration (tmax) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  2. Time to Last Observed Plasma Concentration (tlast) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  3. Terminal rate constant (λz) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  4. Terminal Half-life (t1/2) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  5. Apparent Total Plasma Clearance (CL/F) of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  6. Time to Maximum Observed Effect (tEmax) for ANC of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  7. Area Under Effect Curve from zero to 360 hours (AUEC0-360) for ANC of MSB11455 and Neulasta

    Time frame: Pre-dose up to 15 days post-dose

  8. Safety Profile as Assessed by Clinical Adverse events (AEs), Laboratory Variables, Vital Signs, Incidence of Antidrug Antibodies (ADAs), Neutralizing Antibodies(NABs)

    Safety assessment will be based on number of subjects with AEs, abnormal laboratory variables, abnormal vital signs, incidence of ADAs and NABs

    Time frame: Day 1 up to a maximum of 15 months

07

Study locations

2 sites
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
  • Q-Pharm Pty Ltd
    Herston, 4006, Australia
08

References and documents

Publications

  • Lickliter J, Kanceva R, Vincent E, Schueler A, Harrison-Moench E, Yue CS, Stahl M, Ullmann M, Ghori V, Griffin P. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial. Clin Ther. 2020 Aug;42(8):1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020. Epub 2020 Jul 11. PubMed 32660769 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in May 2018, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 16, 2017
StartActual
Aug 22, 2017
Primary completionActual
May 8, 2018
CompletionActual
Oct 17, 2018
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03251248
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Aug 22, 2017
Primary completion
May 8, 2018
Completion
Oct 17, 2018
Last update
Jul 2, 2019

Study contacts

Radmila Kanceva, MD, PhD
study director · Fresenius Kabi SwissBioSim GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion